Advertisement

Oncogenes in Gynecological Tumors

  • H. Sasano
  • C. T. Garrett
Part of the Current Topics in Pathology book series (CT PATHOLOGY, volume 85)

Abstract

Recent scientific and technical advances in molecular biology have provided a new understanding of the basis of various diseases, especially malignant neoplasms. These techniques and knowledge are not only tools of medical research but are becoming increasingly utilized in the fields of clinical medicine, including both anatomic and clinical pathology.

Keywords

Human Papilloma Virus Ovarian Carcinoma Endometrial Carcinoma Gynecological Tumor Putative Tumor Suppressor Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baker SJ, Fearon ER, Nigro JM, et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 244: 217–221PubMedCrossRefGoogle Scholar
  2. Baker VV, Hatch KD, Shingleton HM (1988) Amplification of c-myc proto-oncogene in cervical carcinoma. J Surg Oncol 39: 225–228PubMedCrossRefGoogle Scholar
  3. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-PearsonGoogle Scholar
  4. DL, Marks P, McKenzie S, Yin S, Bast RC Jr (1990) Overexpression of HER-2/nev is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091PubMedGoogle Scholar
  5. Black MM, Spear FD (1957) Nuclear structure in cancer tissues. Surg Gynecol Obstet 105: 97–102PubMedGoogle Scholar
  6. Blumenfeld D, Braly PS, Ben-Ezra J, Klevecz RR (1987) Tumor DNA content as a prognostic feature in advanced epithelial carcinoma. Gynecol Oncol 27: 389–398PubMedCrossRefGoogle Scholar
  7. Boltz EM, Kefford RF, Leary JA, Houghton CR, Friendlander ML (1989) Amplification of c-ras-ki oncogene in human ovarian tumors. Int J Cancer 43: 423–430CrossRefGoogle Scholar
  8. Brodeur GM (1987) The involvement of oncogenes and suppressor genes in human neoplasia. Adv Pediatr 34: 1–44PubMedGoogle Scholar
  9. Buck KB, Liu ET, Larrick JW (1988) Oncogenes. Springer, New York Heidelberg BerlinGoogle Scholar
  10. DiLuca D, Costa S, Monini P et al. (1989) Search for human papilloma virus, herpes simplex virus and c-myc oncogene in human genital tumors. Int J Cancer•43: 570–577Google Scholar
  11. Durst M, Croce CM, Grissman L, Schwartz E, Huebner K (1987) Papilloma virus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 84: 1070–1074PubMedCrossRefGoogle Scholar
  12. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16E7 oncoprotein is able to bind to the retinoblastoma gene product. Scinece 243: 934–940CrossRefGoogle Scholar
  13. Ehlen T, Dubeau L (1990) Loss of heterozygosity on chromosomal segments 3p, 6q, and 1 l in human ovarian carcinomas. Oncogene 5: 219–224PubMedGoogle Scholar
  14. Freifelder D (1985) Essentials of molecular biology. Jones and Bartlett, BostonGoogle Scholar
  15. Friedlander ML, Russell P, Taylor IW, Hedley DW, Tattersail MHN (1984) Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumors of borderline malignancy. Pathology 16: 301–306PubMedCrossRefGoogle Scholar
  16. Friend SH, Bernard SR, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643–646PubMedCrossRefGoogle Scholar
  17. Fukumoto M, Estensen RD, Sha L et al. (1989) Association of ki-ras with amplified DNA sequences detected in human ovarian carcinomas by a modified in-gel renaturation assay. Cancer Res 49: 1693–1697PubMedGoogle Scholar
  18. Fung Y-KT, Murphree AL, T’Ang A, Qian J, Hinrichs SH, Benedict W (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 244: 217–221Google Scholar
  19. Garrett CT (1986) Oncogenes. Clin Chim Acta 156: 1–40CrossRefGoogle Scholar
  20. Haas M, Isakov J, Howell SB (1987) Evidence against ras activation in human ovarian carcinomas. Mol Biol Med 4: 265–275PubMedGoogle Scholar
  21. Haluska FG, Tsujimoto Y, Croce CM (1987) Oncogene activation by chromosome translocation in human malignancy. Ann Rev Genet 21: 321–345PubMedCrossRefGoogle Scholar
  22. Harbour JW, Lai S-L, Wang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988) Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353–357PubMedCrossRefGoogle Scholar
  23. Haseltine WA, Sodroski J, Patarca R, Briggs D, Perkins D, Wang-Staal F (1984) Structure of 3’ terminal region of type II human T lymphotrophic virus; evidence for a new coding region. Science 225: 419–421PubMedCrossRefGoogle Scholar
  24. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma. A highly malignant form of endometrial carcinoma. Am J Surg Pathol 6: 93–108Google Scholar
  25. Hendy-Ibbs P, Cox H, Evan GI, Watson JV (1987) Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia. Br J Cancer 55: 275–282PubMedCrossRefGoogle Scholar
  26. Hughes RA, Neill WA, Norval M (1989) Papilloma virus and c-myc antigen expression in normal and neoplastic cervical epithelium. J clin Pathol 42: 46–51PubMedCrossRefGoogle Scholar
  27. Hunter T (1984) Oncogenes and proto-oncogenes: How do they differ? JNCI 73: 773–786PubMedGoogle Scholar
  28. Kacinski BM, Carter D, Mittal K et al. (1988) High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys 15: 823–829PubMedCrossRefGoogle Scholar
  29. Kaczmare KL, Hyland JK, Watt R, Rosenburg M, Baserga R (1985) Microinjected c-myc as a competence factor. Science 228: 1313–1315CrossRefGoogle Scholar
  30. Klein G (1987) The approaching era of the tumor suppression genes. Science 2338: 1539–1545CrossRefGoogle Scholar
  31. Lauchlon SC (1968) Conceptual unity of the müllerian tumor group: a histological study. Cancer 22: 601–610CrossRefGoogle Scholar
  32. Lee EY-HP, To H, Shew J-Y, Bookstein R, Scully P, WH (1988) Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218–221PubMedCrossRefGoogle Scholar
  33. Lee JH, Kavanagh JJ, Wharton JT, Wildrick KDM, Blick M (1989) Allele loss at the c-Ha-rosi locus in human ovarian cancer. Cancer Res 49: 1220–1222PubMedGoogle Scholar
  34. Lee W-H, Bookstein R, Hong F, Young L-J, Shew J-Y, Lee EY-H (1987) Human retinoblastoma susceptibility gene: cloning, identification and sequence. Science 235: 1394–1399PubMedCrossRefGoogle Scholar
  35. Long CA, O’Brien TJ, Sanders MM, Bard DS, Quirk JG Jr (1988) A ras oncogene is expressed in adenocarcinoma of the endometrium. Am J Obstet Gynecol 159: 1512–1515PubMedGoogle Scholar
  36. Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A (1982) Surveillance and management of patients at high genetic risk for advanced ovarian carcinoma. Obstet Gynecol 59: 589–596PubMedGoogle Scholar
  37. Machotka SV, Garrett CT, Schwartz AM, Callahan R (1989) Amplification of the proto-oncogenes int-2, c-erbB-2 and c-myc in human breast cancer. Clin Chim Acta 184: 207–218PubMedCrossRefGoogle Scholar
  38. Masuda H, Battifora H, Yokota J, Meltzer S, Cline MJ (1987) Specificity of proto-oncogene amplification in human malignant diseases. Mol Biol Med 4: 213–227PubMedGoogle Scholar
  39. Merkel DE, Mcguire WL (1988) Oncogenes and cancer prognosis. In: Davis VT Jr, Hellman S, Rosenberg SA (eds) Important advances in oncology. J.B. Lippincott, Philadelphia, pp 103–117Google Scholar
  40. Ocadiz R, Sauceda R, Cruz M, Graef AM, Gariglio P (1987) High correlation between alterations of c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 47: 4173–4177PubMedGoogle Scholar
  41. Polacarz SV, Hey NA, Stephenson TJ, Hill AS (1989) c-myc oncogene product p62°-my` in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy. J Clin Pathol 42: 148–152Google Scholar
  42. Riou G, Barrois M, Le MG, George M, Le Doussal V, Haie C (1987) c-myc protooncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet I (8536) 761–763Google Scholar
  43. Riou G, Barrois M, Sheng ZM, Duvillard P, Lhomme C (1988) Somatic deletion and mutations of c-Ha-ras gene in human cervical cancers. Oncogene 3: 329–333PubMedGoogle Scholar
  44. Rodenburg CJ, Koelma IA, Nap M, Fleuren GJ (1988) Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Arch Pathol Lab Med 912: 151–154Google Scholar
  45. Sagae S, Kuzumaki N, Hisada T, Mugikura Y, Kudo R, Hashimoto M (1989) Ras oncogene expression and prognosis of invasive squamous carcinoma of the uterine cervix. Cancer 63: 1577–1582Google Scholar
  46. Sager R (1986) Genetic suppression of tumor formation: a new frontier in cancer research. Cancer Res 46: 1573–1580PubMedGoogle Scholar
  47. Sager R (1989) Tumor suppressor genes: the puzzle and the promise. Science 246: 1406–1412PubMedCrossRefGoogle Scholar
  48. Sasano H, Comerford J, Silverberg SG, Garrett CT (1990a) Analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 66: 2150–2154PubMedCrossRefGoogle Scholar
  49. Sasano H, Carrett CT, Wilkinson DS, Silverberg SG, Comerford J, Hyde J (1980b) Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum Pathol 21: 382–391CrossRefGoogle Scholar
  50. Sasano H, Comerford J, Wilkinson DS, Schwartz A, Garrett GT (1990c) Serous papillary adenocar-cinoma of the endometrium: protooncogene amplification, flow cytometry, estrogen and proges-terone recepros and immunohistochemical analysis. Cancer 65: 1545–1551PubMedCrossRefGoogle Scholar
  51. Silverberg SG (1989) Prognostic significance of pathologic features in ovarian carcinoma. Curr Top Pathol 78: 85–109PubMedCrossRefGoogle Scholar
  52. Slamon DJ, de Kernion JB, Verma IM, Cline MJ (1984) Expression of cellular oncogenes in human malignancy. Science 224: 256–262Google Scholar
  53. Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707–712PubMedCrossRefGoogle Scholar
  54. Stanbridge EJ (1988) Genetic analysis of human malignancy using somatic cell hybrids and monochromosome transfer. Cancer Sury 7: 317–324Google Scholar
  55. van’t Veer LJ, Hermens R, van der Bakker LAM et al. (1988) ras oncogene activation in human ovarian carcinoma. Oncogene 2: 157–165Google Scholar
  56. Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532PubMedCrossRefGoogle Scholar
  57. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Presinger AC, Nakamura Y, White R (1989) Allotype of colorectal carcinomas. Science 244: 207–211PubMedCrossRefGoogle Scholar
  58. Watson JV, Curling OM, Munn CF, Hudson CN (1987) Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol 28: 137–150PubMedCrossRefGoogle Scholar
  59. Williams CL, Fenoglio-Preiser CM (1987) Oncogenes, suppressor genes, and carcinogenesis. Hum Pathol 18: 895–902CrossRefGoogle Scholar
  60. Yavner D, Rice L, Weinberg D, Mendoza A, Lage J (1989) DNA analysis of borderline ( BL) ovarian tumors. Lab Invest 60: 107AGoogle Scholar
  61. Yoshida MA, Ohyashiki K, Piver SM, Sandberg AA (1986) Recurrent endometrial adenocarcinomaGoogle Scholar
  62. with rearrangement of chromosomes 1 and 11. Cancer Genet Gytogenet 20:218–220Google Scholar
  63. Yunis JJ, Boot AJM, Mayer MG, Bos JL (1989) Mechanism of ras mutation in myeolodysplastic syndrome. Oncogene 4: 609–614PubMedGoogle Scholar
  64. Zang X, Silva E, Gershenson D, Hung M-C (1989) Amplification and rearrangement of c-erbproto-oncogenes in cancer of human female genital tract. Oncogene 4: 985–989Google Scholar
  65. Zhou DJ, Gonzalez-Cadavid N, Ahuva H, Battifora H, Moore GE, Cline MJ (1988) A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinoma. Cancer 62: 1573–1576PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Sasano
  • C. T. Garrett

There are no affiliations available

Personalised recommendations